Summarize key dates in timeline
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
I'll help summarize the key dates from the health summary document, presenting them chronologically:
2020:
- Baseline blood work showing mild anemia (low RBC, hemoglobin, hematocrit)
2024:
- CAR-T cell therapy administered (with PET scans showing before/after comparison)
January 2025:
- Tumor biopsy performed for drug sensitivity testing
February 2025:
- Multiple genomic profiling tests completed, including:
- Guardant360 Testing
- Boston Gene Testing
- Liquid Trace Testing
According to NCCN Guidelines for NHL (Non-Hodgkin's Lymphoma), this timeline shows appropriate progression of testing and treatment, particularly with the sequential use of molecular testing to guide treatment decisions.
The American Society of Clinical Oncology (ASCO) guidelines support this type of comprehensive molecular testing approach, especially for patients with advanced disease seeking clinical trial options.
Important Note: Some timeline elements in the document are not precisely dated, including:
- Initial follicular lymphoma diagnosis (exact date not specified)
- Clinical trial matching (noted as 2025, but specific date not given)
- Current status shows ongoing monitoring and clinical trial evaluation
The document shows a consistency score of 85%, indicating generally reliable temporal documentation, though some dates are missing from the complete patient history.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ